Biologics CDMO and Market Growth Accelerating: What the Numbers Mean and What Is Driving Them

Biologics CDMO and Market Growth Accelerating: What the Numbers Mean and What Is Driving Them

SEO Keywords: biologics CDMO market growth, biologics CDMO market size 2025, biologics market CAGR, outsourced biologics manufacturing, monoclonal antibodies CDMO, biosimilars manufacturing, cell gene therapy CDMO, Samsung Biologics Lonza CDMO capacity, BIOSECURE Act CDMO impact, single-use bioreactor biologics, biologics outsourcing pharma

The biologics manufacturing sector is undergoing one of the most significant structural expansions in the history of the pharmaceutical industry. Two parallel markets, the overall biologics market and the contract development and manufacturing organisation (CDMO) segment that supports it, are growing simultaneously at rates that would have seemed implausible a decade ago. Understanding what is driving that growth, who is capturing it, and what structural forces are reshaping the competitive landscape requires looking beyond the headline figures to the underlying dynamics of drug pipelines, geopolitical legislation, technology evolution, and changing economics across the pharmaceutical supply chain.

The Size and Scale of the Biologics Market in 2025

The overall global biologics market is now measured in hundreds of billions of dollars and is growing faster than the broader pharmaceutical market by a substantial margin. According to Precedence Research, the global biologics market was valued at approximately $487 billion in 2025 and is projected to reach approximately $1.14 trillion by 2034, expanding at a compound annual growth rate (CAGR) of approximately 9.96% over that period. Mordor Intelligence places the market value at $412 billion in 2025, estimating growth to $743 billion by 2031 at a CAGR of 10.31%. Grand View Research estimated the market at $400 billion in 2024, projecting growth to $653 billion by 2030 at a CAGR of 8.5%. Across these independent analyses, the consistent picture is a market growing at approximately 9% to 11% annually for the remainder of this decade.

North America dominates the global biologics landscape, accounting for over 40% of global consumption, driven by the presence of major innovator companies, the FDA's streamlined approval pathways including Fast Track and Breakthrough Therapy designations, and high rates of biologic adoption across oncology, immunology, and rare disease segments. Asia-Pacific is the fastest-growing regional market, forecast to expand at a CAGR of approximately 11% through 2034, driven by China, India, and South Korea's rapid buildout of biopharmaceutical manufacturing and research capabilities alongside expanding domestic healthcare access.

By product category, monoclonal antibodies (mAbs) continue to dominate, accounting for approximately 65 to 66% of total biologics market revenue in 2025. Monoclonal antibodies now span oncology, autoimmune diseases, inflammatory conditions, and infectious disease indications, with their predictable pharmacology and decades of manufacturing refinement making them the most commercially mature segment. In 2021, the FDA approved its 100th monoclonal antibody product, just six years after approving its 50th. By 2024, 56 anticancer mAb-based treatments had received FDA approval and 48 had received European Medicines Agency approval.

Beyond mAbs, the next wave of biologic growth is concentrated in cell and gene therapies, which posted a CAGR of 12.11% through 2031 in Mordor Intelligence's modelling, and in antisense and RNAi therapeutics, which are projected to grow at approximately 20.6% to 20.7% CAGR, reflecting the maturation of RNA-based medicine platforms following the mRNA vaccine programmes of the COVID-19 era. Vaccines remain a steady foundational pillar as governments invest in pandemic preparedness, and biosimilars are gaining significant commercial velocity as patent cliffs on blockbuster reference biologics arrive and payers push for cost-effective alternatives. Biosimilars alone saved healthcare systems an estimated $12.4 billion globally in 2023, with savings expected to accelerate as more biosimilars launch across the EU and US markets.

Oncology represents the single largest therapeutic application of biologics, commanding approximately 36 to 40% market share and posting a CAGR of approximately 13.5 to 14% through 2031, driven by the expansion of immunotherapies and CAR-T cell products into earlier lines of treatment. Antibody-drug conjugates (ADCs) and multispecific antibodies are broadening precision oncology by combining targeting domains with cytotoxic or immunomodulatory payloads, representing two of the fastest-growing sub-segments within the broader mAb category. GLP-1 receptor agonists for diabetes and obesity have generated extraordinary commercial demand, most visibly through Novo Nordisk's and Lilly's products, with Novo Nordisk committing $4.1 billion to new fill-finish space to meet demand. This demand surge has been a primary driver of biologic manufacturing capacity investment globally, including Lilly's $800 million Kinsale facility in Ireland.

The Biologics CDMO Market: Structure, Size, and Growth Rate

The biologics CDMO market is the manufacturing and development services layer beneath the broader biologics market. It encompasses all third-party contract development and manufacturing organisations that support pharmaceutical and biotechnology companies in developing, scaling, and commercially producing biologic drug substances and finished products. CDMOs handle activities spanning cell line development, process development, analytical testing, clinical batch production, and large-scale commercial manufacturing of active pharmaceutical ingredients and finished dose forms.

Market sizing estimates for the biologics CDMO segment vary across research firms depending on methodology, scope, and definition. Mordor Intelligence values the market at $25.32 billion in 2025, projecting growth to $38.29 billion by 2031 at a CAGR of 7.14% over the 2026 to 2031 forecast period. Precedence Research calculates a market size of $23.08 billion in 2025, projecting approximately $55 billion by 2035 at a CAGR of 9.14%. Nova One Advisor estimates $22.45 billion in 2024 growing to $25.92 billion in 2025 and $94.60 billion by 2034 at a CAGR of 15.47%. Research and Markets reports growth from $21.3 billion in 2024 to $24.37 billion in 2025 at a CAGR of 14.4%, reaching $42.33 billion by 2029. Technavio forecasts incremental market growth of $16.32 billion between 2024 and 2029 at a CAGR of 13.7%.

The variation in these estimates reflects different definitions of what constitutes the biologics CDMO market, whether analytical services, regulatory support, and fill-finish operations are included, and whether biosimilar manufacturing services are fully captured within scope. The consistent conclusion across all major forecasting sources is that the biologics CDMO market is growing materially faster than the overall pharmaceutical services market, with growth rates in the 7% to 16% range depending on the forecast horizon and scope of analysis.

The most widely cited figures for the near-term market, referenced in the source material for this article, place the market at approximately $22 to $25 billion in 2024 to 2025, growing to $27 billion or above in the immediate short term and continuing to expand through the 2030s.

Why the CDMO Market Is Growing: Six Structural Drivers

1. Pipeline Complexity and the Outsourcing Imperative

‍The growing complexity of next-generation biological therapeutics, including multispecific antibodies, ADCs, cell and gene therapies, and nucleic acid-based medicines, has made in-house manufacturing capability increasingly difficult and expensive to maintain. Building and validating a biologics manufacturing facility requires capital expenditures typically in the hundreds of millions of dollars, followed by years of operational learning to achieve the quality consistency that commercial-scale GMP requires. For most small and mid-sized biotech companies, which hold approximately 70% of the global biopharmaceutical R&D pipeline, building proprietary manufacturing infrastructure is neither economically viable nor strategically desirable. These companies rely on CDMOs to access manufacturing expertise, GMP-compliant infrastructure, and regulatory compliance support that they cannot build or sustain internally. As Frost and Sullivan noted, "rising development costs, reduced profit margins, and stricter price ceilings are driving pharmaceutical companies to outsource services instead of building in-house," with emerging biopharma firms facing the additional constraint that "70% of the R&D pipeline" is held by companies that face significant resource limitations.

2. Capital Efficiency and Asset-Light Strategy

Venture investors are increasingly demanding that biotech portfolio companies pursue asset-light strategies, allocating capital to pipeline advancement rather than manufacturing infrastructure. A company that spends $500 million building a manufacturing plant instead of advancing three additional pipeline assets into clinical trials is making a capital allocation decision that most modern biotech investors would question. CDMOs allow biotech companies to access world-class manufacturing capacity without the upfront capital commitment. Samsung Biologics has secured $13 billion in long-term production contracts with 16 of the top 20 global pharmaceutical firms specifically by offering turnkey biomanufacturing capability that eliminates the need for client capital expenditure in manufacturing infrastructure. This "pay-per-use" model is structurally advantageous for both sponsors and CDMOs, provided the CDMO can maintain the quality consistency, regulatory track record, and capacity availability that large pharma clients require.

3. Technological Innovation: Single-Use Bioreactors and Continuous Bioprocessing

The widespread adoption of single-use bioreactor technologies has fundamentally changed the economics and flexibility of biologics manufacturing at the CDMO level. Single-use systems eliminate the cleaning validation requirements, cross-contamination risks, and turnaround time associated with stainless steel bioreactor systems, enabling CDMOs to run multiple products sequentially through the same manufacturing suite without the regulatory and operational burden of system changeover qualification. This flexibility is particularly valuable for CDMOs handling diverse client portfolios spanning clinical-stage and commercial products.

Continuous bioprocessing, including continuous perfusion bioreactors and integrated downstream processing, is gaining adoption at the CDMO level as a means of increasing throughput, reducing the footprint of manufacturing operations, and improving product quality consistency through real-time process monitoring. Continuous perfusion bioreactors are growing at a CAGR of 12.38% because they can triple productivity compared to fed-batch systems while reducing water and energy consumption. FUJIFILM Diosynth's MaruX continuous manufacturing line and similar installations at other leading CDMOs represent the early commercial rollout of continuous biologics manufacturing at scale, following the conceptual foundation established by regulatory guidance under ICH Q13.

4. The Biosimilars Pipeline and Patent Cliff Dynamics

The approaching patent expiry of several major reference biologics, including blockbuster monoclonal antibodies and biologic insulin analogues, is creating a substantial wave of biosimilar manufacturing demand. CDMOs that can offer dedicated biosimilar manufacturing suites with streamlined EMA and FDA regulatory submission support are particularly well-positioned to capture this segment. Streamlined EMA pathways introduced in 2024 have lowered entry barriers for biosimilar developers, prompting established CDMOs to build dedicated biosimilar manufacturing capacity. The outsourcing segment of the biologics market is projected to grow at a CAGR of 10.7% to 10.8%, faster than in-house manufacturing, precisely because biosimilar developers typically lack proprietary manufacturing infrastructure and rely heavily on CDMOs for both development-stage and commercial-scale production.

5. The BIOSECURE Act and Supply Chain Diversification

One of the most consequential structural forces reshaping the biologics CDMO competitive landscape is geopolitical. The BIOSECURE Act, signed into US law as part of the National Defense Authorization Act in December 2025, prohibits US government agencies and entities receiving federal funding from contracting with biotechnology companies designated as "biotechnology companies of concern." While no companies had been formally designated as of early 2026, the legislation was drafted with specific Chinese companies in mind, including WuXi AppTec and WuXi Biologics, which together serve a substantial portion of the global biopharma outsourcing market.

A survey by the Biotechnology Innovation Organization found that 79% of biopharmaceutical and biotechnology companies have a product or contract with a Chinese contract manufacturing organisation or CDMO, with WuXi AppTec and WuXi Biologics representing the deepest dependencies. A separate July 2024 survey by LEK Consulting found that 26% of life science companies were already looking to shift away from their Chinese partners and 16% would only consider non-Chinese partners going forward. Multiple biopharma companies began diversifying their manufacturing relationships away from Chinese CDMOs in 2024 and 2025, even before the Act was formally signed.

The consequence for the broader CDMO market is significant capacity reallocation. Western CDMOs with available bioreactor capacity and a strong regulatory track record, specifically Lonza, Samsung Biologics, Catalent (now under Novo Holdings), Thermo Fisher Scientific, FUJIFILM Diosynth, Boehringer Ingelheim Biopharmaceuticals, and AGC Biologics, have seen elevated demand for manufacturing commitments as pharma companies seek to establish non-Chinese supply chain redundancy. Total disclosed investment in CDMO capacity reached $24.86 billion in 2025, with 74% of that, approximately $18.48 billion, flowing into the United States. Lonza's $1.2 billion acquisition of Genentech's Vacaville biologics site in California and Samsung Biologics' achievement of full utilisation across 362,000 litres of bioreactor capacity by 2024 are among the clearest market signals of how tightly constrained high-quality Western biologics CDMO capacity has become.

6. Record Biologics Approvals and IND Filing Volumes

The clinical trial pipeline feeding future CDMO demand has itself reached record levels. A 25% jump in 2024 IND filings for biologics underlines the volume of new molecules entering the development funnel. At commercial manufacturing stage, biological drugs now account for nearly half of all new drug approvals in the US. The FDA approved 17 new biologicals for cancer treatment alone in Q2 2024. Seven fresh FDA approvals in 2024 validated allogeneic CAR-T and stem cell products. This approval rate directly drives CDMO commercial manufacturing demand as products transition from clinical to commercial scale.

The Competitive Landscape: Concentration, Scale, and Strategic Positioning

The biologics CDMO market is led by a group of well-established large-scale providers. By revenue, the leading CDMOs in this space include Lonza Group ($7.5 billion total CDMO revenue), Samsung Biologics ($3.2 billion), Catalent (now under Novo Holdings, approximately $4.2 billion in pharma services revenue), Thermo Fisher Scientific ($3.5 billion in pharma services), WuXi Biologics ($2.8 billion), FUJIFILM Diosynth ($2.0 billion), and Boehringer Ingelheim Biopharmaceuticals ($1.8 billion).

Samsung Biologics has been the sector's standout growth performer, posting 20%+ revenue growth in 2024 and guiding for 20%+ growth in 2025. In the second half of 2024 alone, Samsung Biologics won three separate contracts each exceeding $1 billion in value, including a single contract worth approximately $1.24 billion with an unnamed Asia-based pharmaceutical company, effective through 2037. Samsung's total bioreactor capacity exceeded 780,000 litres by 2025, which is shifting biosimilar manufacturing economics toward scale-driven pricing and positioning Samsung as the third-largest global CDMO by revenue. The competitive landscape is also rapidly consolidating through major M&A: Novo Holdings' $16.5 billion acquisition of Catalent and Lonza's $1.2 billion acquisition of Genentech's Vacaville site are the most significant recent transactions, reducing the number of independent large-scale capacity providers.

Specialist niche CDMOs including Rentschler Biopharma and KBI Biopharma are gaining prominence in viral vector manufacturing for gene therapies and complex proteins, where scale-leaders have less dominance. FUJIFILM Diosynth Biotechnologies and Thermo Fisher Scientific differentiate through proprietary technology platforms and single-use bioreactor capabilities. WuXi Biologics faces the ongoing challenge of the BIOSECURE Act's implications, despite not having been formally designated as of early 2026, with the uncertainty itself causing some clients to diversify away from WuXi while it retains existing contractual relationships.


What This Growth Trajectory Means for Clinical Research and Trial Operations

The biologics CDMO market's growth is not simply a manufacturing story. It has direct implications for clinical research timelines, drug availability, and the feasibility of late-stage trial supply.

The tightening of Western biologics CDMO capacity, driven by the BIOSECURE Act decoupling dynamics and raw demand growth, means that clinical-stage companies are facing longer lead times for GMP manufacturing slots, higher pricing for commercial and late-stage clinical manufacturing, and greater urgency in locking in CDMO partnerships earlier in development. For organisations sponsoring clinical trials in biologics, including monoclonal antibodies, ADCs, cell and gene therapies, and nucleic acid therapeutics, the CDMO landscape that existed two years ago is structurally different from the one they are operating in today.

The record 25% jump in IND filings for biologics in 2024 is accelerating the queue for flexible multi-product clinical manufacturing capacity. CDMOs with rapid changeover capability, platform processes, and end-to-end CRDMO (contract research, development and manufacturing) services spanning discovery through commercial supply are becoming preferred partners for pipeline-heavy biotech clients precisely because they reduce the number of technology transfer events, regulatory filings, and manufacturing relationships a sponsor must manage simultaneously. WuXi Biologics' February 2025 partnership with Candid Therapeutics, valued at $925 million for trispecific T-cell engager manufacturing, and SK pharmteco's $260 million Sejong facility announcement in the same month are the most recent large-scale signals of where the clinical supply chain investment is flowing.

For those working across clinical operations, regulatory affairs, and manufacturing strategy in the life sciences sector, the biologics CDMO market's growth trajectory is not background market intelligence. It is the operating environment that determines which molecules reach patients on time, at what cost, and with what supply chain resilience. The numbers are large. The implications are larger.

Sources: Mordor Intelligence Biologics CDMO Market Report 2026-2031, Precedence Research Biologics CDMO Market 2025-2035, Nova One Advisor Biologics CDMO Market 2024-2034, Grand View Research Biologics CDMO Market Report 2033, Technavio Biologics CDMO Market 2024-2029, Research and Markets Biologics CDMO Market Report, Frost and Sullivan Biologics CDMO Growth Opportunities 2024-2029, Bourne Partners CDMO Report March 2025, Vision Lifesciences CDMO Market Analysis 2026, Foley Hoag LLP BIOSECURE Act Analysis, Greenberg Traurig BIOSECURE Act Insights, C&EN BIOSECURE Act Analysis, Precedence Research Biologics Market, Grand View Research Biologics Market, Mordor Intelligence Biologics Market 2026-2031, BioSpace market releases, Healthcare IB Guide BIOSECURE Act analysis.